The firm said the clinical trial pause is temporary as an independent data monitoring committee finalizes its analysis for submission to regulators.

U.S. IND clearance follows recent approval of CTA for EPI-321 in facioscapulohumeral muscular dystrophy (FSHD) in New Zealand ...

Hemogenyx Pharmaceuticals Files Annual IND Report with FDA for HG-CT-1 CAR-T Therapy for AML LONDON, UK / ACCESS Newswire / April 3, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to annou ...

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

New research on Structure Research is the subject of a report. According to news reporting from Sao Paulo, Brazil, by NewsRx journalists, research stated,“ Spot bitcoin ETFs have been recently ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer. Initiation of trial sites underway for ground ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Copyright 2025 The Associated Press. All Rights Reserved. The U.S. Food and Drug Administration building behind FDA logos at a bus stop on the agency’s campus in ...